Literature DB >> 12925350

Cartilage tissue engineering using cryogenic chondrocytes.

Goutham K Gorti1, Justin Lo, Sassan Falsafi, Jon Kosek, Susan Y Quan, Duke T Khuu, R James Koch.   

Abstract

OBJECTIVE: To generate in vitro hyaline cartilage from cryogenically preserved human septal chondrocytes in a simulated microgravity environment on a 3-dimensional biodegradable scaffolding material.
METHODS: In this experiment, cryogenically frozen chondrocytes were thawed and cultured in a monolayer in serum-based chondrocyte media. They were seeded onto 3-dimensional biopolymer scaffolds in a spinner flask. The seeded constructs were then transferred to a bioreactor (an environment of solid-body rotation) for 6 weeks. Chondrocyte growth and extracellular matrix production in the constructs were confirmed by cell count, cell viability, and histologic analysis and by electron microscopy.
RESULTS: Histologic sections stained with hematoxylin-eosin and Alcian blue (for acidic proteoglycans) confirmed the presence of hyaline cartilage in the cartilage constructs. Ultrastructural examination using transmission electron microscopy demonstrated matrix formation and chondrocyte viability.
CONCLUSIONS: This study proves that chondrocytes that are cryogenically stored for extended periods can be used to grow cartilage in vitro. Cryogenically preserved chondrocytes retain their ability to grow in tissue culture, redifferentiate, and produce extracellular matrix.

Entities:  

Mesh:

Year:  2003        PMID: 12925350     DOI: 10.1001/archotol.129.8.889

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  2 in total

1.  Culture of human septal chondrocytes in a rotary bioreactor.

Authors:  Marsha S Reuther; Van W Wong; Kristen K Briggs; Angela A Chang; Quynhhoa T Nguyen; Barbara L Schumacher; Koichi Masuda; Robert L Sah; Deborah Watson
Journal:  Otolaryngol Head Neck Surg       Date:  2012-05-17       Impact factor: 3.497

Review 2.  Engineering cartilage tissue.

Authors:  Cindy Chung; Jason A Burdick
Journal:  Adv Drug Deliv Rev       Date:  2007-10-05       Impact factor: 15.470

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.